UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gastrointestinal stromal tumors: what do we know now?

Modern pathology, 2014-01, Vol.27 (Suppl 1), p.S1-S16

Corless, Christopher L

2014

Volltextzugriff (PDF)

Gastrointestinal stromal tumour

The Lancet (British edition), 2013-09, Vol.382 (9896), p.973-983

2013

Volltextzugriff (PDF)

Gastrointestinal stromal tumours: origin and molecular oncology

Nature reviews. Cancer, 2011-12, Vol.11 (12), p.865-878

2011

Volltextzugriff (PDF)

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease

PloS one, 2015-08, Vol.10 (8), p.e0136407

2015

Volltextzugriff (PDF)

Gastrointestinal stromal tumour

The Lancet (British edition), 2007-05, Vol.369 (9574), p.1731-1741

2007

Volltextzugriff (PDF)

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Journal of clinical oncology, 2015-08, Vol.33 (24), p.2617-2622

2015

Volltextzugriff (PDF)

Molecular pathobiology of gastrointestinal stromal sarcomas

Annual review of pathology, 2008-01, Vol.3 (1), p.557-586

2008

Volltextzugriff (PDF)

Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval

Journal of clinical oncology, 2021-05, Vol.39 (15), p.1674-1686

2021

Volltextzugriff (PDF)

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2904-2909

2011

Volltextzugriff (PDF)

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

Clinical cancer research, 2009-12, Vol.15 (24), p.7510-7518

2009

Volltextzugriff (PDF)

Biology of Gastrointestinal Stromal Tumors

Journal of clinical oncology, 2004-09, Vol.22 (18), p.3813-3825

2004

Volltextzugriff (PDF)

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Journal of clinical oncology, 2015-03, Vol.33 (9), p.1000-1007

2015

Volltextzugriff (PDF)

Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes

The American journal of surgical pathology, 2009-03, Vol.33 (3), p.437-446

2009

Volltextzugriff (PDF)

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5352-5359

2008

Volltextzugriff (PDF)

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3182-3190

2013

Volltextzugriff (PDF)

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Journal of clinical oncology, 2008-02, Vol.26 (4), p.620-625

2008

Volltextzugriff (PDF)

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5360-5367

2008

Volltextzugriff (PDF)

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors

Journal of translational medicine, 2016-12, Vol.14 (1), p.339-339, Article 339

2016

Volltextzugriff (PDF)

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3605-3610

2010

Volltextzugriff (PDF)

NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas—a study of 4569 cases

Modern pathology, 2020-05, Vol.33 (5), p.924-932

2020

Volltextzugriff (PDF)

Next-Generation Sequencing in Cancer Diagnostics

The Journal of molecular diagnostics : JMD, 2016-11, Vol.18 (6), p.813-816

Corless, Christopher L

2016

Volltextzugriff (PDF)

KIT Gene Mutations and Copy Number in Melanoma Subtypes

Clinical cancer research, 2008-11, Vol.14 (21), p.6821-6828

2008

Volltextzugriff (PDF)

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4764-4774

2006

Volltextzugriff (PDF)

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions

Journal of thoracic oncology, 2017-08, Vol.12 (8), p.e107-e110

2017

Volltextzugriff (PDF)

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data

The Journal of molecular diagnostics : JMD, 2015, Vol.17 (1), p.53-63

2015

Volltextzugriff (PDF)

1 – 25 von 471

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(445)
Mit Volltextzugriff
(361)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(471)

Erscheinungsjahr

n.n

Thema

Science & Technology
(316)
Life Sciences & Biomedicine
(302)
Humans
(273)
Female
(161)
Male
(144)
Biological And Medical Sciences
(129)
Middle Aged
(123)
Medical Sciences
(122)
Mutation
(102)
Oncology
(99)
Adult
(97)
Tumors
(95)
Pathology
(93)
Aged
(76)
Proto-Oncogene Proteins C-Kit - Genetics
(62)
Surgery
(59)
Animals
(58)
Immunohistochemistry
(53)
Gastrointestinal Stromal Tumors - Genetics
(45)
Imatinib Mesylate
(45)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Gastrointestinal stromal tumors: what do we know now?

Gastrointestinal stromal tumour

Gastrointestinal stromal tumours: origin and molecular oncology

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease

Gastrointestinal stromal tumour

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Molecular pathobiology of gastrointestinal stromal sarcomas

Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

Biology of Gastrointestinal Stromal Tumors

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas—a study of 4569 cases

Next-Generation Sequencing in Cancer Diagnostics

KIT Gene Mutations and Copy Number in Melanoma Subtypes

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data

Suchergebnisse filtern